Literature DB >> 25709134

Pharmacoepidemiology of antiretroviral drugs in a teaching hospital in Lagos, Nigeria.

I A Oreagba1, S O Usman2, S O Olayemi2, K A Oshikoya3, O Opanuga4, T A Adeyemo5, O A Lesi4, A N Dodoo6, A S Akanmu5.   

Abstract

OBJECTIVE: Prescribing, adherence, and adverse drug events to HAART in a large antiretroviral programme in Lagos was evaluated.
DESIGN: A retrospective 5 year open cohort study.
SETTING: The AIDS Prevention Initiative in Nigeria (APIN) clinic at LUTH is one of the United States Presidential Emergency Plan for AIDS Relief (PEP-FAR) funded centers for HIV relief program in Nigeria Participants The case files of 390 patients on HAART and attending the APIN clinic were reviewed sequel to random selection. MAIN OUTCOME MEASURES: Demographics of the patients and pattern of antiretroviral (ARV) combination drugs prescribed were extracted from their case files. The details of the adverse drug events (ADEs) were extracted from drug toxicity forms regularly filled for each patient. A Chi-square test with Yates correction was used to determine the association between adherence and therapeutic outcome.
RESULTS: A total of 2944 prescriptions were assessed. Zidovudine + lamivudine + nevirapine (35.87%) and stavudine + lamivudine + nevirapine (35.63%) were the most frequently prescribed combinations. Over 2000 ADEs were reported with cough (13.3%), fever (8.75%) and skin rashes (8.01%) being the most frequently reported. Drug adherence was associated with good therapeutic outcome (χ(2) = 115.60, p<0.0001).
CONCLUSIONS: Zidovudine + lamivudine + nevirapine was the most frequently prescribed ARV combination. Cough was the most frequently reported ADE. Interventions aimed at rational prescribing of ARV drugs and improving adherence to antiretroviral drugs is essential for good therapeutic outcome in the treatment of HIV infection.

Entities:  

Keywords:  Pharmacoepidemiology; adverse events; antiretroviral drugs; drug adherence

Mesh:

Substances:

Year:  2014        PMID: 25709134      PMCID: PMC4335432          DOI: 10.4314/gmj.v48i4.5

Source DB:  PubMed          Journal:  Ghana Med J        ISSN: 0016-9560


  29 in total

1.  Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring.

Authors:  J H Arnsten; P A Demas; H Farzadegan; R W Grant; M N Gourevitch; C J Chang; D Buono; H Eckholdt; A A Howard; E E Schoenbaum
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

2.  Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.

Authors:  Mark S Sulkowski; David L Thomas; Shruti H Mehta; Richard E Chaisson; Richard D Moore
Journal:  Hepatology       Date:  2002-01       Impact factor: 17.425

Review 3.  International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations.

Authors:  R Haubrich; L Demeter
Journal:  J Acquir Immune Defic Syndr       Date:  2001-03-01       Impact factor: 3.731

4.  Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Authors:  J P Fagot; M Mockenhaupt; J N Bouwes-Bavinck; L Naldi; C Viboud; J C Roujeau
Journal:  AIDS       Date:  2001-09-28       Impact factor: 4.177

5.  Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.

Authors:  A d'Arminio Monforte; A C Lepri; G Rezza; P Pezzotti; A Antinori; A N Phillips; G Angarano; V Colangeli; A De Luca; G Ippolito; L Caggese; F Soscia; G Filice; F Gritti; P Narciso; U Tirelli; M Moroni
Journal:  AIDS       Date:  2000-03-31       Impact factor: 4.177

6.  Sex differences in nevirapine rash.

Authors:  S J Bersoff-Matcha; W C Miller; J A Aberg; C van Der Horst; H J Hamrick; W G Powderly; L M Mundy
Journal:  Clin Infect Dis       Date:  2000-12-13       Impact factor: 9.079

7.  Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

Authors:  E Martínez; J L Blanco; J A Arnaiz; J B Pérez-Cuevas; A Mocroft; A Cruceta; M A Marcos; A Milinkovic; M A García-Viejo; J Mallolas; X Carné; A Phillips; J M Gatell
Journal:  AIDS       Date:  2001-07-06       Impact factor: 4.177

8.  Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy.

Authors:  Rachel Jordan; Lisa Gold; Carole Cummins; Chris Hyde
Journal:  BMJ       Date:  2002-03-30

9.  Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors.

Authors:  Graeme J Moyle; Debasis Datta; Sundhiya Mandalia; John Morlese; David Asboe; Brian G Gazzard
Journal:  AIDS       Date:  2002-07-05       Impact factor: 4.177

10.  Evaluation of the adverse reactions of antiretroviral drug regimens in a tertiary care hospital.

Authors:  Zahoor A Rather; Mukta N Chowta; G J K Prakash Raju; Faheem Mubeen
Journal:  Indian J Pharmacol       Date:  2013 Mar-Apr       Impact factor: 1.200

View more
  3 in total

1.  A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.

Authors:  Comfort Kunak Ogar; Abiodun Abiola; Daniel Yuah; Ali Ibrahim; Ibrahim Adekunle Oreagba; Emmanuel C Amadi; Mojisola Christianah Adeyeye; Kazeem Adeola Oshikoya
Journal:  Pharmaceut Med       Date:  2019-04

2.  Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.

Authors:  Olufunsho Awodele; Rebecca Aliu; Ibrahim Ali; Yetunde Oni; Christianah Mojisola Adeyeye
Journal:  Pharmacol Res Perspect       Date:  2018-10

3.  Antiretroviral-induced adverse drug reactions in HIV-infected patients in Mali: a resource-limited setting experience.

Authors:  Aboubacar Alassane Oumar; Mamadou Dakouo; Anicet Tchibozo; Mamoudou Maiga; Guida Landouré; Raysso Abdi-Bogoreh; Paul M Tulkens; Sounkalo Dao; Jean Cyr Yombi
Journal:  Int J Basic Clin Pharmacol       Date:  2019-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.